Search
Olokizumab
go.drugbank.com/drugs/DB13127InvestigationalTargeting IL-6 function can be achieved directly, or through interrupting the IL-6 receptor or gp130 receptor axes. … Interleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system.
Florantyrone
go.drugbank.com/drugs/DB08975ApprovedWithdrawnFlorantyrone is used in the treatment of biliary dyskinesia
SR-9011
go.drugbank.com/drugs/DB14014ExperimentalSR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues
Rilmenidine
go.drugbank.com/drugs/DB11738ApprovedWithdrawnRilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.
Products: Iterium 1 mg - Tabletten, HYPERIUM 1 MG TABLET, 30 ADETIsoxaflutole
go.drugbank.com/drugs/DB12938ApprovedWithdrawnBalance has been investigated for the treatment of Chronic Renal Failure and Peritoneal Membrane Disorder.
Dichlorotetrafluoroethane
go.drugbank.com/drugs/DB20118ApprovedWithdrawnDichlorotetrafluoroethane has a monoisotopic molecular weight of 169.93 Da.
Iopydone
go.drugbank.com/drugs/DB20831ApprovedWithdrawnIopydone has a monoisotopic molecular weight of 346.83 Da.
Secretin porcine
go.drugbank.com/drugs/DB09527ApprovedWithdrawnSecretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.
Ebastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Products: EBASTINA EG, KESTINE TABLET 10 mgFucoxanthin
go.drugbank.com/drugs/DB15462Investigational, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. … Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).